Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001104659-25-013268·ADAMS STREET PARTNERS LLC
Schedule 13G ownership disclosure
Mineralys Therapeutics Inc
Common Stock · CUSIP: 603170101
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Adams Street Partners, LLC
Shares: 1,129,807.00 · Class: 2.3%
- Adams Street 2016 Direct Venture/Growth Fund LP
Shares: 91,126.00 · Class: 0.2%
- Adams Street 2017 Direct Venture/Growth Fund LP
Shares: 117,878.00 · Class: 0.2%
- Adams Street 2018 Direct Venture/Growth Fund LP
Shares: 176,038.00 · Class: 0.4%
- Adams Street 2019 Direct Growth Equity Fund LP
Shares: 98,889.00 · Class: 0.2%
- Adams Street 2020 Direct Growth Equity Fund LP
Shares: 105,448.00 · Class: 0.2%
- Adams Street 2021 Direct Growth Equity Fund LP
Shares: 102,305.00 · Class: 0.2%
- Adams Street Growth Equity Fund VII LP
Shares: 438,123.00 · Class: 0.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-013268
- Form type
- SCHEDULE 13G/A
- Filer
- ADAMS STREET PARTNERS LLC
- CIK
- CIK 1193586
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership